

# QUARTERLY INVESTMENT REVIEW

## International Developed Equity Allocation Fund

### Performance returns (USD)

ANNUALIZED RETURNS (QUARTER-END)	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
International Developed Equity Allocation Fund (net)	-4.28	10.64	10.64	5.45	6.95	5.47	4.44
International Developed Equity Allocation Fund (gross)	-4.13	11.33	11.33	6.11	7.61	6.12	5.08
MSCI EAFE	-8.11	3.82	3.82	1.64	4.73	5.20	3.87
Value Add	+3.84	+6.81	+6.81	+3.81	+2.23	+0.27	+0.57

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower. Gross of fees, expenses and transaction costs, if any. If these fees, expenses and costs were included, performance would be lower. **Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit [www.gmo.com](http://www.gmo.com).** Returns include a substantial, one-time litigation settlement recovery received on December 16, 2024. This event contributed 3.24% to Q4 2024 and 3.75% to 2024 annual performance. Performance for other periods, including this date, was also positively impacted, sometimes materially. Without this recovery, performance would have been lower in both absolute terms and relative to the benchmark. Additional information is available upon request.

### MAJOR PERFORMANCE DRIVERS

– The overweight exposure to Emerging Market equities has been reduced to zero over the course of 2024 and the portfolio is now aligned with the benchmark from a top-down regional perspective, investing solely in Developed ex-U.S. equities. The strategy does have a notable overweight to Japan, however, and this had a small positive impact for the quarter as MSCI Japan outperformed MSCI EAFE.

– Security selection was strong as the broader Developed ex-U.S. exposure outperformed its benchmark.

Developed ex-U.S. equities, including the dedicated Japan Value position, accounted for all the equity exposure of the portfolio for the quarter, and so had no impact on relative performance versus the MSCI EAFE benchmark. Security selection was solid for the quarter and the equity portfolio returned -7.2% in aggregate, ahead of the MSCI EAFE index return of 8.1%. Underweight positions in Novo Nordisk (Denmark Health Care) and Nestle (Switzerland Consumer Staples), along with overweight positions in Panasonic Holdings (Japan Consumer Discretionary), Oversea-Chinese Banking Corp (Singapore Financials), and 3i Group (UK Financials) made up the top five biggest individual contributors at the total portfolio level. On the flipside, overweight positions in Sumitomo Forestry (Japan Consumer Discretionary) and GSK (UK Health Care), along with underweight positions in Mitsubishi UFJ (Japan Financials), Toyota Motor (Japan Consumer Discretionary), and SAP (Germany Information Technology) made up the top five biggest detractors.

Portfolio weights, as a percent of equity, for the positions mentioned were: Oversea-Chinese Banking Corp (1.6%), Nestle (0.0%), Mitsubishi UFJ (0.0%), Panasonic Holdings (1.2%), 3i Group (2.2%), Sumitomo Forestry (1.3%), GSK (2.1%), Novo Nordisk (0.1%), Toyota Motor (0.0%), SAP (0.5%).

Inception Date: 5-Jun-06

Performance for the year of inception is less than a full calendar year. Returns shown for periods greater than one year are on an annualized basis.

**Risks:** Risks associated with investing in the Fund may include: (1) Market Risk - Equities: The market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. (2) Non-U.S. Investment Risk: The market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. (3) Management and Operational Risk: The risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility. For a more complete discussion of these risks and others, please consult the Fund's Prospectus. **Performance Returns:** Annualized Returns may include the impact of purchase premiums and redemption fees. The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

**Net Expense Ratio: 0.62%; Gross Expense Ratio: 0.67%** Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least June 30, 2025. Elimination of this reimbursement will result in higher fees and lower performance. Gross Expense Ratio is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated June 30, 2024.

# QUARTERLY INVESTMENT REVIEW

## PRODUCT OVERVIEW

The GMO International Developed Equity Allocation Fund seeks to generate total return greater than that of the MSCI EAFE Index.

The philosophy that underlies all of GMO's Asset Allocation investment strategies is the belief that, at times and in the short term, the pricing of asset classes can deviate from true intrinsic value but mean reverts to appropriate valuation levels over a complete market cycle. Using GMO's 7-Year Asset Class Forecasts, the Fund seeks to allocate to areas of the global equity markets we believe are most attractively valued. Our approach combines the best of GMO's top-down Asset Allocation views and bottom-up equity research to identify mispricings at both the asset class and individual security levels. The Fund allocates to equity strategies that are actively managed by other GMO investment teams with expertise and experience in security selection within their respective markets. The Fund is allowed to invest up to 10% (at time of purchase) in emerging market equities.

## IMPORTANT INFORMATION

**Benchmark(s):** The MSCI EAFE (Europe, Australasia, and Far East) Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of international large and mid capitalization stocks. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

**An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit [www.gmo.com](http://www.gmo.com). Read the prospectus carefully before investing.**

The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

## ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO\*

SINGAPORE

SYDNEY

TOKYO\*\*

\*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

\*\*Representative Office

[www.GMO.com](http://www.GMO.com)